OCULOGENEX
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.
OCULOGENEX
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2020-01-01
Address:
La Habra, California, United States
Country:
United States
Website Url:
http://www.oculogenex.com
Total Employee:
1+
Status:
Active
Contact:
562-726-4424
Total Funding:
281 K USD
Similar Organizations
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Valted Seq
Valted Seq is a discovery stage biopharmaceutical company that utilizes big data to develop lifesaving therapeutics.
Current Employees Featured
Founder
Investors List
MassChallenge
MassChallenge investment in Non Equity Assistance - Oculogenex
MassChallenge
MassChallenge investment in Non Equity Assistance - Oculogenex
National Science Foundation
National Science Foundation investment in Grant - Oculogenex
Official Site Inspections
http://www.oculogenex.com
- Host name: box5877.bluehost.com
- IP address: 162.241.24.143
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Oculogenex"
Oculogenex - Crunchbase Company Profile & Funding
Organization. Oculogenex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Oculogenex is a biopharmaceutical company that …See details»
About Us - Oculogenex
Dr. Lu has a broad background in clinical and basic sciences, with specific training and expertise in cell culture, ophthalmology, neuroscience and diabetes. His long-term goal is to facilitate the development of a therapeutic for …See details»
Oculogenex Company Profile: Overview and Full News Analysis
Oculogenex has garnered recognition for its groundbreaking work, being selected as one of LA's Best biotech companies and participating in the MassChallenge Boston competition, a non …See details»
Macular Degeneration Research Heads to the ISS - ISS …
CAPE CANAVERAL (FL), March 14, 2024 – Age-related macular degeneration (AMD) is a leading cause of blindness in older adults, affecting more than 200 million people globally. Patients in the intermediate stage of the disease …See details»
ISS National Lab-sponsored study tests a novel gene therapy for …
Mar 14, 2024 Oculogenex received funding for this investigation through the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space, …See details»
Oculogenex and Forge Biologics Announce AAV Contract …
Jan 10, 2023 LA HABRA, Calif., and COLUMBUS, Ohio – January 10, 2023 – Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to …See details»
Oculogenex Company Profile 2024: Valuation, Funding & Investors …
Oculogenex General Information Description. Operator of a biopharmaceutical company intended to focus on the development of gene therapy to treat retinal disorders. The company's ocular …See details»
Oculogenex's AMD gene therapy to undergo testing in …
Mar 20, 2024 Oculogenex is participating in the ISS National Laboratory-sponsored investigation as part of the ISS’s sponsored programs, which provide organizations with a unique research platform and the flexibility to explore key …See details»
Oculogenex conducting macular degeneration …
Mar 29, 2024 Oculogenex received funding for this investigation through the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space, manager of the ISS National Lab, in …See details»
Oculogenex - VentureRadar
Oculogenex was founded by an ophthalmologist committed to developing better treatment options for her patients with blinding retinal diseases. Not satisfied with the fact that so many patients …See details»
Oculogenex - Contacts, Employees, Board Members, Advisors
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders.See details»
Forge Biologics and Oculogenex Announce AAV Contract …
Jan 10, 2023 Media Inquiries—Oculogenex Ram Ramkumar, Ph.D. [email protected] Client Development—Forge Biologics John Maslowski Chief Commercial Officer …See details»
ISS National Lab-sponsored study to test a novel gene therapy for …
Mar 17, 2024 To address this, an ISS National Laboratory-sponsored investigation by Oculogenex will validate spaceflight as a novel biologic model of intermediate AMD. It will …See details»
How gene-therapy treated space mice may help us treat vision …
Jun 21, 2024 This week, biotech Oculogenex landed an early, but essential, endorsement from the Food and Drug Administration (FDA), the company’s CEO and founder Hema Ramkumar …See details»
Clinical Trials - Oculogenex
Oculogenex plans to start human clinical trials for intermediate AMD in late 2025. If you or someone you know would like to participate in the trial, please contact …See details»
3/25 Gene Therapy to Treat AMD to be Tested in Space
Mar 20, 2024 Oculogenex’s gene therapy is designed to target the root causes of dry macular degeneration at the intermediate stage. Because macular degeneration disproportionately …See details»
Oculogenex Embarks on Space Mission for AMD Gene Therapy
Mar 18, 2024 Oculogenex, Inc. has introduced a pioneering gene therapy aimed at treating age-related macular degeneration (AMD), set for a novel test on the International Space Station …See details»
Forge Biologics and Oculogenex Announce AAV Contract
Jan 10, 2023 LA HABRA, Calif. & COLUMBUS, Ohio--(BUSINESS WIRE)-- Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to …See details»
Our Product - Oculogenex
Our investigational therapy is a novel ocular regenerative gene therapy product that is delivered one-time into the eye with an intraocular injection.See details»